MS Called Valeant "House of Cards" When Pitching Allergan

Mark Melin

Published onJune 16, 2014

Updated on May 13, 2021

Senior executives from Morgan Stanley (NYSE:MS), now said to be a key consultant to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), called Valeant a “house of cards,” in an e-mail to Allergan, Inc. (NYSE:AGN) management saying “your investors should not want to take their stock.”

Allergan has kicked up its pressure on the stock price of Valeant

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

MS Called Valeant "House of Cards" When Pitching Allergan

Allergan has kicked up its pressure on the stock price of Valeant

Login required to continue reading.

Get Your Business News